By: Chris Ryan From: onclive.com The combination of eftilagimod alpha and paclitaxel produced a modest increase in median overall survival (OS) in patients with endocrine-resistant hormone receptor (HR)–positive/HER2-negative metastatic breast cancer; though, the effects were significant in patients younger than 65 years old, had low monocytes, or had more aggressive disease (luminal B), according to a post hoc analysis of …
Gilead, Merck to study combination therapy for breast cancer
By: PBR Staff Writer From: pharmaceutical-business-review.com Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients with metastatic triple-negative breast cancer (TNBC). Gilead Sciences and Merck have signed an agreement to assess the efficacy of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda (pembrolizumab) to treat patients …
Men with Stage IV breast cancer who are receptive to systemic therapy benefit from surgery
Source: American College of Surgeons From: news-medical.net Men with Stage IV breast cancer and known estrogen (ER) and progesterone receptor (PR) status benefit from surgical intervention and from trimodal therapy (systemic therapy, surgery, and radiation), according to a study presented at the virtual American College of Surgeons (ACS) Clinical Congress 2021. The National Comprehensive Cancer Network guidelines to treat men …
Elacestrant extends PFS in advanced breast cancer
From: healio.com A randomized phase 3 trial designed to evaluate elacestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer met both of its primary endpoints, according to the agent’s manufacturer. Results showed the agent extended PFS compared with investigator’s choice of hormonal agent in the overall study population and the subgroup of those with estrogen receptor 1 (ESR1) …
New ESMO Clinical Practice Guideline for managing metastatic breast cancer released
Source: European Society for Medical Oncology (ESMO) From: news-medical.net The much-anticipated ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer has been published today in Annals of Oncology. Amidst public information and support initiatives taking place worldwide on the occasion of Breast Cancer Awareness Month, the publication marks a milestone for the translation …
Lawrence + Memorial Hospital Using Precision Medicine to Treat Breast Cancer
Submitted by: Emily Montemerlo From: medicine.yale.edu Yale New Haven Health is bringing precision medicine to breast cancer patients at Lawrence + Memorial Hospital (L+M) with a new imaging agent that is designed specifically to detect certain types of recurrent or metastatic breast cancer. Last year for the first time, the Food and Drug Administration (FDA) approved a Positron Emission Tomography …
Veru Launches Registrational Trial of Anti-Androgen Drug Enobosarm for Metastatic Breast Cancer
From: precisiononcologynews.com Veru, a Miami-based cancer drugmaker, on Wednesday said it has begun enrolling previously treated hormone receptor (HR)-positive, HER2-negative metastatic breast cancer patients in a Phase III trial of its anti-androgen receptor therapy enobosarm. The registration-directed trial, dubbed ARTEST, is specifically exploring the activity of enobosarm in advanced breast cancer patients with androgen receptor (AR)-positive and estrogen receptor (ER)-positive …
More Data Needed on Tissue-Agnostic Therapy Use in Breast Cancer
By: Emily Brill From: ajmc.com A new report suggests that much remains to be seen about tissue-agnostic therapies’ effectiveness for treating breast cancer, as “a paucity of data” exists regarding this relatively new treatment’s impact on the disease, and that additional studies are needed to evaluate how well these therapies work on treating metastatic breast cancer (mBC). The investigators reviewed …
Trodelvy Improves QOL in Triple-Negative Breast Cancer
By: Greg Laub From: medpagetoday.com At the European Society for Medical Oncology (ESMO) virtual meeting, new data from the phase III ASCENT study was presented showing that patients with treatment-resistant metastatic triple-negative breast cancer (TNBC) who received sacituzumab govitecan (Trodelvy) had significant and clinically meaningful improvements in health-related quality of life (QOL). In this exclusive MedPage Today video, co-investigator Kevin …
Clinical Challenges: Surgery for De Novo Metastatic Breast Cancer?
By: Diana Swift From: medpagetoday.com Questions remain about whether there is any benefit to removing an intact primary tumor About 6% of newly diagnosed breast cancer patients present at initial diagnosis with de novo metastatic disease and an intact primary tumor. Understandably, many such patients will want to have that tumor removed at the outset. Over the past 2 decades, …